GW&K Investment Management LLC Has $26.33 Million Holdings in NeoGenomics, Inc. $NEO

GW&K Investment Management LLC grew its position in NeoGenomics, Inc. (NASDAQ:NEO) by 7.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,238,767 shares of the medical research company’s stock after acquiring an additional 155,882 shares during the quarter. GW&K Investment Management LLC’s holdings in NeoGenomics were worth $26,328,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Cerity Partners LLC lifted its stake in shares of NeoGenomics by 17.5% in the 4th quarter. Cerity Partners LLC now owns 32,323 shares of the medical research company’s stock valued at $380,000 after purchasing an additional 4,814 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of NeoGenomics in the 4th quarter valued at $121,000. State of Wyoming lifted its stake in shares of NeoGenomics by 41.3% in the 4th quarter. State of Wyoming now owns 28,232 shares of the medical research company’s stock valued at $332,000 after purchasing an additional 8,248 shares during the last quarter. Moors & Cabot Inc. lifted its stake in shares of NeoGenomics by 12.7% in the 4th quarter. Moors & Cabot Inc. now owns 15,500 shares of the medical research company’s stock valued at $182,000 after purchasing an additional 1,750 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of NeoGenomics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock valued at $37,364,000 after purchasing an additional 44,733 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $11.28 on Thursday. The business has a fifty day simple moving average of $8.93 and a 200 day simple moving average of $10.32. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -14.65 and a beta of 1.82. NeoGenomics, Inc. has a one year low of $4.72 and a one year high of $13.74.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $186.67 million for the quarter, compared to the consensus estimate of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The firm’s revenue was up 11.3% compared to the same quarter last year. Sell-side analysts expect that NeoGenomics, Inc. will post -0.15 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on NEO shares. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and increased their price target for the company from $12.00 to $25.00 in a report on Wednesday, April 29th. UBS Group reiterated a “hold” rating on shares of NeoGenomics in a report on Wednesday, February 18th. Weiss Ratings upgraded NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Zacks Research cut NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 20th. Finally, Benchmark raised NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Wednesday, April 29th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, NeoGenomics has an average rating of “Hold” and a consensus price target of $13.86.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.